Business Wire

Nuclera Acquires E Ink Digital Microfluidics Unit

Share

Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ink technology, are pleased to announce the acquisition of E Ink’s digital microfluidics unit into the newly formed US subsidiary of Nuclera. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005575/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Nuclera desktop bioprinter powered by digital microfluidic technology. (Photo: Business Wire)

Nuclera has been working in a strategic partnership with E Ink since 2018 to deploy Nuclera’s proprietary biopolymer synthesis technologies on E Ink’s digital microfluidic devices. Instead of the physical channels found in conventional microfluidics, digital microfluidics uses electronic signals to guide microdroplets. When combined with Nuclera biopolymer synthesis, this advanced lab-on-a-chip technology will enable a user to digitally program the next day bioprinting of proteins and genes on a desktop device. The result is a bioprinter that gives unprecedented access to biology. Commercialization is expected in 2022.

In the transaction, E Ink will contribute intellectual property, equipment, and highly specialized scientists and engineers. Reciprocally, E Ink will become the largest strategic shareholder in Nuclera. The resulting Nuclera US subsidiary will be co-located within the E Ink Innovation Center in Billerica, MA, a short distance from the growing biotech technology hub in Cambridge, MA. The combination of these two efforts into one company will further increase the rate of development, commercialization, and adoption of this ground-breaking product as well as consolidate the intellectual property position. E Ink will continue to be a strategic supplier to Nuclera for key electronic components of Nuclera’s desktop bioprinter.

Dr. Michael Chen, Co-founder and CEO of Nuclera, commented: “Our partner, E Ink, made reading accessible by printing words with electronic ink. We are proud to work with E Ink to make biology accessible by printing biology with digital microfluidics. This acquisition allows Nuclera to combine the biological with the digital in one product and under one roof. We now look forward to further strengthening our strategic partnership with E Ink through joint R&D, manufacturing, and product development projects.”

Dr. Michael McCreary, Chief Innovation Officer of E Ink said: “This spinout and ongoing relationship with Nuclera gives E Ink the opportunity to leverage our knowledge and capabilities in electronic paper technology into the growing biotechnology sector which has increasingly critical importance to the current and future challenges in global health and sustainability. We are pleased to be able participate in this market through an equity stake in Nuclera and look forward to the continuing relationship as a strategic supplier to and equity partner with Nuclera.”

For more information, about Nuclera, visit https://www.nuclera.com.

About Nuclera

Nuclera is the leading pioneer in making biology accessible through desktop enzymatic protein and gene synthesis. Headquartered in Cambridge, UK, Nuclera was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins and genes. Three exciting Nuclera technologies protected by 45+ patents enable Nuclera’s desktop bioprinter: enzymatic protein synthesis, enzymatic gene synthesis, and digital microfluidics. The combination of these technologies in a deployable desktop bioprinting platform create an unprecedented one-stop shop ecosystem that enables Nuclera to provide consistent biological workflows, products, and information to its customers. To be a part of Nuclera’s effort or to simply learn more, please visit www.nuclera.com.

About E Ink Holdings

E Ink Holdings Inc. (8069.TW), based on technology from MIT’s Media Lab, has transformed and defined the eReader market, enabling a new multi-billion dollar market in less than 10 years. E Ink’s low power products are ideal for IoT applications ranging from retail, home, hospital, transportation and more, enabling customers to put displays in locations previously impossible. The Company’s corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays. For more information please visit www.eink.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nuclera:
Andrew Fellows; E: andrewf@alto-marketing.com; T: +44(0)1489 557672
Direct Nuclera media enquiries; E: media@nuclera.com

E Ink:
Anna Halstead, Racepoint Global, 617-624-3492, eink@racepointglobal.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine21.6.2021 14:01:00 CEST | Press release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic factors may contribute to underdiagnosis of migraine across society1. A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patients with migraine across the geographic area studied. Prevalence rates were positively associated with the socio-economic status of the geographic area studied, suggesting that those living with migraine from less advantaged areas may find it harder to achieve an accurate diagnosis and thereby access appropriate therapy. “These findings are concerning not least because they suggest significant ‘migraine awareness inequity’ in this population,” said Professor Gal Ifergane, study investigator, practitioner, head of the Depart

New Data Supporting the Safety and Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European Academy of Neurology Congress21.6.2021 14:01:00 CEST | Press release

A new analysis presented by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on AJOVY® (fremanezumab) injection for the preventive treatment of migraine, indicates to the European neurology community that the medicine has a positive safety profile in relation to risk of cardiovascular events. The data, drawn from an analysis of three published Phase 3 studies of fremanezumab and presented at the 7th Congress of the European Academy of Neurology (EAN), showed minimal changes in the heart rate and blood pressure of those patients studied over a 12 week period. 1 “As a CGRP inhibitor, fremanezumab has been shown to provide protection against migraine in suitable patients, and we remain focused on continued assessment of the safety profile of this therapy, particularly in relation to heart-related issues as it is believed CGRP itself acts as a ‘safeguard’ during cardiovascular ischemia and other events,” said Dr Joshua M. Cohen, Senior Director and Global Therapeutic Area Lead, Mi

Ezbob Introduces New SaaS Platform to Meet the Changing Landscape of Digital Banking21.6.2021 11:00:00 CEST | Press release

Ezbob Ltd., an innovator in customer acquisition technology for financial services, today announced the introduction of a new modular SaaS platform that addresses key trends in the sector. The company’s Ezbob Express™, focuses on three important needs: offering financial service providers the flexibility of filling gaps in their digital transformation strategies, enabling them to make more precise complex credit and risk decisions in real-time, and facilitating the growth of embedded finance. Ezbob’s new Express customer acquisition platform has a modular approach, enabling financial institutions with gaps in their digital channel to add the functionality needed to achieve a customised digital experience. The new modules include: UX & Process Design, Compliance & Authentication, Credit & Risk Decisioning and Product Recommender. Since its inception Ezbob has been providing digital onboarding services for many well-known financial institutions including Santander, NatWest, Metro Bank, P

Ambarella Expands Security AI Vision SoC Portfolio With Two New Families; Doubles Resolution to 32MP30 for 4K Multi-Imager Cameras With Advanced AI21.6.2021 11:00:00 CEST | Press release

Ambarella, Inc. (NASDAQ: AMBA), an AI vision silicon company, today announced the expansion of its AI vision SoC portfolio with the new CV5S and CV52S security families. Based on the CVflow® architecture and advanced 5nm process technology, the new SoCs support simultaneous 4K encoding and advanced AI processing in a single low-power design, which provides industry-leading edge AI SoC performance per watt. The CV5S family is ideal for security camera applications that require multiple sensors for 360-degree coverage, over a wide area and with a long range, such as outdoor city environments or large buildings. The CV52S family is designed for single-sensor security cameras with advanced AI performance that need to more clearly identify individuals or objects in a scene, including faces and license plate numbers over long distances, such as ITS traffic cameras. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005178/en/ Am

Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction21.6.2021 10:36:00 CEST | Press release

The European Commission has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and Company have announced.The extension of the indication follows a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) on 20 May 2021.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005298/en/ “Today’s approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction,” said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. “New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and mor

SK Capital Reaches Agreement to Sell Niacet for $1,015m21.6.2021 10:00:00 CEST | Press release

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it reached agreement to sell Niacet Corp. (“Niacet”) to Kerry Group plc, the global taste and nutrition company, for $1,015m (€853m¹) on a cash-free, debt-free basis, subject to customary closing adjustments. Following the acquisition, Niacet will be integrated into Kerry’s global food protection and preservation platform. Jack Norris, Managing Director at SK Capital, said, “SK Capital is privileged to have partnered with Kelly Brannen and the entire Niacet team. We are proud and appreciative of Niacet’s accomplishments over the last four years leveraging the strong foundation the Brannen family built over many decades. We believe Niacet is well-positioned to continue this growth and flourish under Kerry’s ownership. We wish Kerry and all the employees of Niacet every success.” Kelly Brannen, CEO and significant minority owner of Niacet, commented, “We are proud of the rich heritage we have bui

ISAE-SUPAERO's "Collaborative Rover and Drone" Project, Facilitating the Exploration of the Moon21.6.2021 09:54:00 CEST | Press release

While Thomas Pesquet launched on April 22 as part of the Alpha mission, one of humanity's biggest challenges remains even further away than the ISS, 400,000 km from Earth: the establishment of a lunar base. But before being able to settle on the Moon in a prolonged way to exploit its resources or as a logistic support for future exploration missions further away, an exploration work is necessary. The use of autonomous robotic systems would allow mapping of dangerous or hard-to-reach areas from space, before eventually deploying infrastructure such as a spaceport or human habitation. Faced with this exploration challenge, the Space Advanced Concepts Laboratory (SaCLaB) of ISAE-SUPAERO in Toulouse and a team of students from the Institute are developing the Collaborative Rover and Drone (CoRoDro) project to study navigation and autonomous operations for space robotic systems. This scientific study is one of 12 university technology projects selected in 8 different countries as part of th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom